These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19276671)

  • 1. Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
    Takai H; Kato A; Kinoshita Y; Ishiguro T; Takai Y; Ohtani Y; Sugimoto M; Suzuki M
    Cancer Biol Ther; 2009 May; 8(10):930-8. PubMed ID: 19276671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
    Ishiguro T; Sugimoto M; Kinoshita Y; Miyazaki Y; Nakano K; Tsunoda H; Sugo I; Ohizumi I; Aburatani H; Hamakubo T; Kodama T; Tsuchiya M; Yamada-Okabe H
    Cancer Res; 2008 Dec; 68(23):9832-8. PubMed ID: 19047163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
    Nakano K; Ishiguro T; Konishi H; Tanaka M; Sugimoto M; Sugo I; Igawa T; Tsunoda H; Kinoshita Y; Habu K; Orita T; Tsuchiya M; Hattori K; Yamada-Okabe H
    Anticancer Drugs; 2010 Nov; 21(10):907-16. PubMed ID: 20847643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
    Ikeda M; Ohkawa S; Okusaka T; Mitsunaga S; Kobayashi S; Morizane C; Suzuki I; Yamamoto S; Furuse J
    Cancer Sci; 2014 Apr; 105(4):455-62. PubMed ID: 24521523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
    Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
    Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
    Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
    Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
    Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
    Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
    Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
    Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
    Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
    Bell MM; Gutsche NT; King AP; Baidoo KE; Kelada OJ; Choyke PL; Escorcia FE
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
    Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
    Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-3 antibodies: a new therapeutic target for liver cancer.
    Feng M; Ho M
    FEBS Lett; 2014 Jan; 588(2):377-82. PubMed ID: 24140348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.
    Caraballo Galva LD; Jiang X; Hussein MS; Zhang H; Mao R; Brody P; Peng Y; He AR; Kehinde-Ige M; Sadek R; Qiu X; Shi H; He Y
    Hepatology; 2022 Aug; 76(2):330-344. PubMed ID: 34897774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
    Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
    Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma.
    Takai H; Kato A; Kato C; Watanabe T; Matsubara K; Suzuki M; Kataoka H
    Liver Int; 2009 Aug; 29(7):1056-64. PubMed ID: 19141032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nano-particulate Toll-like Receptor 9 Agonist Potentiates the Antitumor Activity of Anti-Glypican-1 Antibody.
    Saito Y; Takahashi T; Hiramatsu K; Serada S; Fujimoto M; Ohkawara T; Sugase T; Nishigaki T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Yamasaki M; Ishii KJ; Eguchi H; Doki Y; Naka T
    Anticancer Res; 2023 Jun; 43(6):2425-2432. PubMed ID: 37247902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
    Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
    Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma.
    Liu Q; Song Q; Luo C; Wei J; Xu Y; Zhao L; Wang Y
    Mol Immunol; 2023 Oct; 162():125-132. PubMed ID: 37677989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.